OK did he really say that? He did not think DC VAX works? I think not. That’s why he’s looking at other immune therapies. He knows that immune therapy does work. He just wants to perhaps use a new way of achieving the efficacy of immunotherapy.
Did you read the part that he was very happy because the immune cells were increased by 10 fold? Or you skipped that part on purpose. Did you see how many folds t cells were increased after receiving DCVax-L? By now, you should know that all the other cancer vaccines can only trigger CD8 t cells and sporadically trigger CD4 t cells. As a matter of fact, from the Nature preprint, CD4 t cells outnumbered CD8 t cells in the case of DCVax-L.
I believe that you’re drifting off way too far from Earth 🌎️ … It sounds like you’re misinformed and need better sources of information, or you’re just reposting baseless mud. It is advisable to seek full-context credible sources and consult licensed oncologists.
Amid all of the misinformation and bad-faith disinformation pollution online, it is crucial that we refocus our attention beyond baseless social media posts to consider better sources…
For a reliable appraisal of the DCVax-L P3 trial, its design, and the significance of the resulting survival data, it is advisable to refer to the analyses of qualified physicians. One such analysis can be found on the JAMA Oncology website where the link to the independent peer review and supplementary materials are published.
JAMA Oncology is a peer-reviewed medical journal that us part of the Journal of the American Medical Association (JAMA) network, which is one of the most widely respected and influential medical journal publishers globally.
Being a peer-reviewed journal means that research articles submitted to JAMA Oncology undergo a thorough evaluation process by independent experts in the field before they are accepted for publication. This process helps ensure the quality, validity, and scientific rigor of the research presented in the journal.
Researchers, healthcare professionals, and the medical community rely on publications like JAMA Oncology for up-to-date and credible information in the field of oncology.
This study found that autologous tumor lystate-loaded dendritic cell vaccination plus standard of care (SOC) was associated with improved survival in both newly diagnosed & recurrent glioblastoma compared with matched controls who received SOC treatment. https://t.co/Uso7Pkh1Kt